{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:10:56Z","timestamp":1791090656208,"version":"4.1.0"},"reference-count":55,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2008,10,31]]},"DOI":"10.2217\/14796694.4.5.611","type":"journal-article","created":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T09:42:12Z","timestamp":1224150132000},"page":"611-621","source":"Crossref","is-referenced-by-count":21,"title":["Nilotinib: A Phenylamino-Pyrimidine Derivative with Activity Against BCR-ABL, KIT and PDGFR Kinases"],"prefix":"10.1080","volume":"4","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[{"name":"UT MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd., Houston, TX77030, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"UT MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd., Houston, TX77030, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"key":"e_1_3_2_3_1_1","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic Leukemia","volume":"132","author":"Nowell P","year":"1960","unstructured":"Nowell P , HungerfordD: A minute chromosome in human chronic granulocytic LeukemiaScience132, 1497 (1960).","journal-title":"Science"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0711"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2139"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403426"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00096-X"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp038130"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3659"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00979-3"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3097"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504952102"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5486.1938"},{"key":"e_1_3_2_3_18_1","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).","volume":"62","author":"Nagar B","year":"2002","unstructured":"Nagar B , BornmannWG, PellicenaPet al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).Cancer Res.62, 4236\u20134243 (2002).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00191-0"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00190-9"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0609239103"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.2.690"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4687"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603170"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio799"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/372746a0"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2601"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004580"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-010132"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-015347"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-026377"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-058032"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.577"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079666"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025217"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.04.005"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0484"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2324"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.03.012"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1932"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.319"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0429"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403785"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-057521"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_3_2_3_49_1","article-title":"Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP).","volume":"25","author":"Jabbour E","year":"2007","unstructured":"Jabbour E , le CoutreP, BaccaraniMet\u00a0al.: Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP).Proc. Am. Soc. Clin. Oncol.25, abstract 7039 (2007).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083196"},{"key":"e_1_3_2_3_51_1","article-title":"Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib.","volume":"110","author":"Giles F","year":"2007","unstructured":"Giles F , LarsonRA, KantarjianKet al.: Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib.Blood110, abstract 1025 (2007).","journal-title":"Blood"},{"key":"e_1_3_2_3_52_1","article-title":"Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC).","volume":"110","author":"Giles F","year":"2007","unstructured":"Giles F , le CoutreP, BhallaKNet\u00a0al.: Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC).Blood110, abstract 1029 (2007).","journal-title":"Blood"},{"key":"e_1_3_2_3_53_1","article-title":"Efficacy of nilotinib (AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP).","volume":"110","author":"Cortes J","year":"2007","unstructured":"Cortes J , O\u2019BrienS, JabbourEet al.: Efficacy of nilotinib (AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP).Blood110, abstract 29 (2007).","journal-title":"Blood"},{"key":"e_1_3_2_3_54_1","article-title":"A Phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) \u2013 study update.","volume":"25","author":"Von Mehren M","year":"2007","unstructured":"Von Mehren M , ReichardtP, CasaliPGet al.: A Phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) \u2013 study update.Proc. Am. Soc. Clin. Oncol.25, abstract 10.23 (2007).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_2_3_55_1","article-title":"A Phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosinophilic syndrome (HES).","volume":"108","author":"le Coutre P","year":"2006","unstructured":"le Coutre P , HochhausA, HeimDet al.: A Phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosinophilic syndrome (HES).Blood108, abstract 4912 (2006).","journal-title":"Blood"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14796694.4.5.611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:08Z","timestamp":1719124988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14796694.4.5.611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,16]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10,31]]}},"alternative-id":["10.2217\/14796694.4.5.611"],"URL":"https:\/\/doi.org\/10.2217\/14796694.4.5.611","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,16]]}}}